In last trading session, Neumora Therapeutics Inc (NASDAQ:NMRA) saw 1.59 million shares changing hands with its beta currently measuring 2.31. Company’s recent per share price level of $1.4 trading at -$0.05 or -3.45% at ring of the bell on the day assigns it a market valuation of $226.44M. That closing price of NMRA’s stock is at a discount of -1127.86% from its 52-week high price of $17.19 and is indicating a premium of 56.43% from its 52-week low price of $0.61. Taking a look at company’s average trading volume for last 10-days demonstrates a volume of 1.77 million shares which gives us an average trading volume of 1.20 million if we extend that period to 3-months.
For Neumora Therapeutics Inc (NMRA), analysts’ consensus is at an average recommendation of Buy while assigning it a mean rating of 2.14. Splitting up the data highlights that, out of 3 analysts covering the stock, 0 rated the stock as a Sell while 0 recommended an Overweight rating for the stock. 0 suggested the stock as a Hold whereas 3 see the stock as a Buy. 0 analyst(s) advised it as an Underweight.
Neumora Therapeutics Inc (NASDAQ:NMRA) trade information
Upright in the red during last session for losing -3.45%, in the last five days NMRA remained trading in the green while hitting it’s week-highest on Wednesday, 07/16/25 when the stock touched $1.4 price level, adding 11.39% to its value on the day. Neumora Therapeutics Inc’s shares saw a change of -87.33% in year-to-date performance and have moved 37.25% in past 5-day. Neumora Therapeutics Inc (NASDAQ:NMRA) showed a performance of 65.78% in past 30-days. Number of shares sold short was 14.54 million shares which calculate 15.45 days to cover the short interests.
Wall Street analysts have assigned a consensus price target of 2 to the stock, which implies a rise of 30.0% to its current value. Analysts have been projecting 2 as a low price target for the stock while placing it at a high target of 2. It follows that stock’s current price would drop -42.86% in reaching the projected high whereas dropping to the targeted low would mean a loss of -42.86% for stock’s current value.
In 2025, company’s earnings growth rate is likely to be around 7.19% while estimates for its earnings growth in next 5 years are of 13.70%.
Neumora Therapeutics Inc (NASDAQ:NMRA)’s Major holders
Insiders are in possession of 27.57% of company’s total shares while institution are holding 60.19 percent of that, with stock having share float percentage of 83.10%. Investors also watch the number of corporate investors in a company very closely, which is 60.19% institutions for Neumora Therapeutics Inc that are currently holding shares of the company. FMR LLC is the top institutional holder at NMRA for having 8.62 million shares of worth $84.76 million. And as of 2024-06-30, it was holding 5.4235 of the company’s outstanding shares.
The second largest institutional holder is SOFTBANK GROUP CORP., which was holding about 7.65 million shares on 2024-06-30. The number of shares represents firm’s hold over 4.8099 of outstanding shares, having a total worth of $75.17 million.
On the other hand, VANGUARD INDEX FUNDS-Vanguard Total Stock Market Index Fund and iShares Trust-iShares Russell 2000 ETF are the top two Mutual Funds which own company’s shares. As of Mar 31, 2025 , the former fund manager was holding 2.32 shares of worth $3.25 million or 1.44% of the total outstanding shares. The later fund manager was in possession of 2.08 shares on May 31, 2025 , making its stake of worth around $2.92 million in the company or a holder of 1.29% of company’s stock.
